psychedelics

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

News

MindMed says LSD-based therapy effective in anxiety

Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an

News

Cybin preps for ph3 as psychedelic clears depression trial

Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.

R&D

Reducing the stigma attached to psychedelics

It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health

News

Otsuka makes psychedelics play, buying Mindset

Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.